指南与共识神经头颈PETMRCT

使用(68)Ga-DOTATATE PET/CT 的切除后脑膜瘤共识放射治疗计划指南

Consensus Radiation Treatment Planning Guidelines Using (68)Ga-DOTATATE PET/CT For Resected Meningiomas.
指南 / 共识 · Int J Radiat Oncol Biol Phys · 2024-12-19

该共识针对术后需辅助放疗的脑膜瘤,基于5例术后临床相关病例的(68)Ga-DOTATATE PET/CT与增强T1加权MRI,由19位国际专家形成靶区勾画共识。多数病例PET勾画允许针对残留病灶更精确地剂量递增至66-70 Gy;与RTOG 0539及现代临床试验勾画指南相比,在无影像或病理脑/骨侵犯证据时,PET引导计划推荐的手术腔临床靶体积外扩更小。

要点

  • 术后脑膜瘤靶区勾画可参考本共识,PET引导下多数病例可针对残留病灶剂量递增至66-70 Gy。
  • 无影像或病理脑/骨侵犯证据时,PET引导计划推荐的手术腔临床靶体积外扩小于RTOG 0539及现代临床试验勾画指南。
  • 共识基于5例病例和19位国际专家,整合入临床可能实现更精确的生物标志物引导放疗。

核心结论

  • 本报告为常见临床情形下接受术后放疗的脑膜瘤提供了共识靶体积勾画指南,整合入临床实践可能实现更精确的生物标志物引导放疗并使未来脑膜瘤临床试验的放疗标准化。

研究设计与样本

  • 共识指南制定;从一项前瞻性单机构登记中选取5例术后临床相关脑膜瘤病例,每例均有术前和术后增强T1加权容积MRI及术后(68)Ga-DOTATATE PET/CT;19位国际专家评估每例并形成共识推荐。

关键影像表现/征象

  • 生长抑素受体2几乎普遍表达于脑膜瘤组织。
  • 基于生长抑素受体的(68)Ga-DOTATATE PET显像可检测到MRI无法辨别的额外或残留病变。

诊断标准与关键数值

  • 多数病例基于PET勾画允许针对残留病变更精确地剂量递增至66-70 Gy。
  • 与RTOG 0539及现代临床试验勾画指南相比,在无影像或病理脑或骨侵犯证据时,PET引导放疗计划推荐的手术腔临床靶体积外扩更小。

临床应用与阅片要点

  • 术后脑膜瘤靶区勾画可参考本共识推荐。
  • PET引导计划在无影像或病理脑或骨侵犯证据时,手术腔临床靶体积外扩可小于RTOG 0539及现代临床试验勾画指南。
  • 多数病例可基于PET勾画针对残留病变剂量递增至66-70 Gy。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Meningiomas are the most common primary intracranial tumor. Somatostatin receptor 2 is almost universally expressed in meningioma tissue. For patients who require adjuvant radiation, somatostatin receptor based (68)Ga-DOTATATE positron emission tomography (PET) imaging can detect additional or residual disease not discernible on magnetic resonance imaging. PET guided radiation treatments may improve local control, minimize toxicity by allowing for more precise radiation therapy plans, and allow for more precise dose-escalation to maximize local control. The aim of this study was to develop consensus PET guided treatment planning guidelines for common meningioma presentations.

METHODS AND MATERIALS: Five postoperative clinically relevant meningioma cases were selected from a prospective single-institutional registry of patients. Each patient had a preoperative and postoperative contrast-enhanced T1-weighted volumetric magnetic resonance imaging, and a postoperative (68)Ga-DOTATATE PET/CT, to assist with target delineation. The full treatment scenario including clinical history, histology, surgical history, and imaging were provided for each patient. Nineteen international experts who have published on the treatment and management of meningiomas, and who use (68)Ga-DOTATATE PET/CT in their practice, evaluated each case. Individual prescription recommendations were created, pooled, and discussed to create consensus recommendations.

RESULTS: Consensus recommendations were created for each case. In most cases, PET-based contouring allowed for more precise dose-escalation to 66-70 Gy targeting residual disease. When compared to RTOG 0539 and modern clinical trial contouring guidelines, a smaller clinical target volume expansion from the surgical cavity was recommended using PET guided radiation plans in the absence of radiographic or pathologic evidence of brain or bone invasion.

CONCLUSIONS: This report provides consensus target volume delineation guidelines for meningiomas receiving postoperative radiation in common clinical situations. Integration of these guidelines into clinical practice may allow for more precise biomarker guided radiation treatments and standardize radiation therapy on future meningioma clinical trials.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Perlow HK, Raleigh DR, Wang TJC, et al. Consensus Radiation Treatment Planning Guidelines Using (68)Ga-DOTATATE PET/CT For Resected Meningiomas. Int J Radiat Oncol Biol Phys. 2024. PMID: 39701546. doi:10.1016/j.ijrobp.2024.12.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。